Jeannette Potts
Compliance Officer at UNIQURE N.V.
Net worth: 502 320 $ as of 2024-03-30
Profile
Jeannette Potts is currently the Secretary, Senior Vice President & General Counsel at Forma Therapeutics Holdings, Inc. and also holds the position of Chief Legal & Compliance Officer at uniQure NV.
Previously, she worked as the Director-Marketing & Sales at Viroblock SA and as the Associate General Counsel at Millennium Pharmaceuticals, Inc. She was also the VP, Head Counsel-Research & Development at Takeda Pharmaceuticals U.S.A., Inc. from 2013 to 2019.
Dr. Potts holds a doctorate degree from the University of Virginia, an undergraduate degree from Smith College, a graduate degree from Suffolk University, and an undergraduate degree from Trinity College Dublin.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
UNIQURE N.V.
0.20% | 2024-02-29 | 96,600 ( 0.20% ) | 502 320 $ | 2024-03-30 |
Jeannette Potts active positions
| Companies | Position | Start |
|---|---|---|
| FORMA THERAPEUTICS HOLDINGS, INC. | General Counsel | 2019-08-31 |
| UNIQURE N.V. | Compliance Officer | - |
Former positions of Jeannette Potts
| Companies | Position | End |
|---|---|---|
Takeda Pharmaceuticals U.S.A., Inc.
 Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Chief Tech/Sci/R&D Officer | 2019-07-31 |
Viroblock SA
 Viroblock SA Miscellaneous Commercial ServicesCommercial Services Viroblock SA develops and commercializes antiviral products. Viroblock technology uses a novel mechanism of action to inactivate enveloped viruses, human and avian such As influenzas, SARS virus and the AIDS virus. The company was founded by Donald F. H. Wallach in 2005 and is headquartered in Irvine, CA. | Sales & Marketing | - |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Training of Jeannette Potts
| University of Virginia | Doctorate Degree |
| Smith College | Undergraduate Degree |
| Suffolk University | Graduate Degree |
| Trinity College Dublin | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| UNIQURE N.V. | Health Technology |
| Private companies | 4 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Viroblock SA
Viroblock SA Miscellaneous Commercial ServicesCommercial Services Viroblock SA develops and commercializes antiviral products. Viroblock technology uses a novel mechanism of action to inactivate enveloped viruses, human and avian such As influenzas, SARS virus and the AIDS virus. The company was founded by Donald F. H. Wallach in 2005 and is headquartered in Irvine, CA. | Commercial Services |
Forma Therapeutics Holdings, Inc.
 Forma Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. engages in the research, development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA. | Health Technology |
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Health Technology |
- Stock Market
- Insiders
- Jeannette Potts